Trial Profile
Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 Sep 2022
Price :
$35
*
At a glance
- Drugs Dendritic cell vaccines (Primary) ; Pidilizumab (Primary)
- Indications Multiple myeloma
- Focus Pharmacodynamics
- 05 Sep 2022 Planned primary completion date changed from 1 Jul 2022 to 1 Jul 2023.
- 02 Aug 2021 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.
- 02 Aug 2021 Planned primary completion date changed from 1 Jul 2021 to 1 Jul 2022.